Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents
Vicky Mody, Joanna Ho, Savannah Wills, et al.
Communications Biology (2021) Vol. 4, Iss. 1
Open Access | Times Cited: 219

Showing 1-25 of 219 citing articles:

Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines
Andrew Bryant, Theresa A Lawrie, Therese Dowswell, et al.
American Journal of Therapeutics (2021) Vol. 28, Iss. 4, pp. e434-e460
Open Access | Times Cited: 230
Therapeutic potential of pyrrole and pyrrolidine analogs: an update
N. Jeelan Basha, S. M. Basavarajaiah, K. Shyamsunder
Molecular Diversity (2022) Vol. 26, Iss. 5, pp. 2915-2937
Open Access | Times Cited: 119
Catalytic Dyad Residues His41 and Cys145 Impact the Catalytic Activity and Overall Conformational Fold of the Main SARS-CoV-2 Protease 3-Chymotrypsin-Like Protease
Juliana C. Ferreira, Samar Fadl, Adrian J. Villanueva, et al.
Frontiers in Chemistry (2021) Vol. 9
Open Access | Times Cited: 110
Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review
Xin Li, Yongcheng Song
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115772-115772
Open Access | Times Cited: 52
SARS-CoV-2 Drug Resistance and Therapeutic Approaches
Sania Batool, Santosh Chokkakula, Ju Hwan Jeong, et al.
Heliyon (2025) Vol. 11, Iss. 2, pp. e41980-e41980
Open Access | Times Cited: 3
Inhibition of the SARS-CoV-2 3CLpro main protease by plant polyphenols
Miha Bahun, Marko Jukič, Domen Oblak, et al.
Food Chemistry (2021) Vol. 373, pp. 131594-131594
Open Access | Times Cited: 101
Thyroid and COVID-19: a review on pathophysiological, clinical and organizational aspects
Giuseppe Lisco, Anna De Tullio, Emilio Jirillo, et al.
Journal of Endocrinological Investigation (2021) Vol. 44, Iss. 9, pp. 1801-1814
Open Access | Times Cited: 100
Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice
Ju Hwan Jeong, Santosh Chokkakula, Seong Cheol Min, et al.
Antiviral Research (2022) Vol. 208, pp. 105430-105430
Open Access | Times Cited: 68
Herbal Remedies, Nutraceuticals, and Dietary Supplements for COVID-19 Management: An Update
Vivek P. Chavda, Aayushi Patel, Disha R. Vihol, et al.
Clinical Complementary Medicine and Pharmacology (2022) Vol. 2, Iss. 1, pp. 100021-100021
Open Access | Times Cited: 63
The mechanisms of action of ivermectin against SARS-CoV-2—an extensive review
Asiya Kamber Zaidi, Puya Dehgani‐Mobaraki
The Journal of Antibiotics (2021) Vol. 75, Iss. 2, pp. 60-71
Open Access | Times Cited: 62
The battle between host and SARS-CoV-2: Innate immunity and viral evasion strategies
Shilei Zhang, Lulan Wang, Genhong Cheng
Molecular Therapy (2022) Vol. 30, Iss. 5, pp. 1869-1884
Open Access | Times Cited: 60
Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2
Kaifu Gao, Rui Wang, Jiahui Chen, et al.
Chemical Reviews (2022) Vol. 122, Iss. 13, pp. 11287-11368
Open Access | Times Cited: 58
Recent Drug Development and Medicinal Chemistry Approaches for the Treatment of SARS‐CoV‐2 Infection and COVID‐19
Arun K. Ghosh, Jennifer L. Mishevich, Andrew D. Mesecar, et al.
ChemMedChem (2022) Vol. 17, Iss. 22
Open Access | Times Cited: 44
SARS-CoV-2 Non-Structural Proteins and Their Roles in Host Immune Evasion
Zheng Yao Low, Nur Zawanah Zabidi, Ashley Jia Wen Yip, et al.
Viruses (2022) Vol. 14, Iss. 9, pp. 1991-1991
Open Access | Times Cited: 38
Discovery of Natural Bisbenzylisoquinoline Analogs from the Library of Thai Traditional Plants as SARS-CoV-2 3CLPro Inhibitors: In Silico Molecular Docking, Molecular Dynamics, and In Vitro Enzymatic Activity
Nopawit Khamto, Kraikrit Utama, Suriya Tateing, et al.
Journal of Chemical Information and Modeling (2023) Vol. 63, Iss. 7, pp. 2104-2121
Closed Access | Times Cited: 25
Development of a GC-376 Based Peptidomimetic PROTAC as a Degrader of 3-Chymotrypsin-like Protease of SARS-CoV-2
Deborah Grifagni, Elena Lenci, Alessia De Santis, et al.
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 2, pp. 250-257
Closed Access | Times Cited: 14
Systematic Reevaluation of Repurposed Drugs Against the Main Protease of SARS‐CoV‐2 via Combined Experiments
Jialu Ye, Rui Zhang, Jiahao Zhou, et al.
Journal of Medical Virology (2025) Vol. 97, Iss. 2
Closed Access | Times Cited: 1
An overview of potential inhibitors targeting non-structural proteins 3 (PLpro and Mac1) and 5 (3CLpro/Mpro) of SARS-CoV-2
Fangfang Yan, Feng Gao
Computational and Structural Biotechnology Journal (2021) Vol. 19, pp. 4868-4883
Open Access | Times Cited: 49
Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication
Zheng Yao Low, Ashley Jia Wen Yip, Sunil K. Lal
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2021) Vol. 1868, Iss. 2, pp. 166294-166294
Open Access | Times Cited: 42
A Review of the Current Landscape of SARS-CoV-2 Main Protease Inhibitors: Have We Hit the Bullseye Yet?
Guillem Macip, Pol Garcia‐Segura, Júlia Mestres‐Truyol, et al.
International Journal of Molecular Sciences (2021) Vol. 23, Iss. 1, pp. 259-259
Open Access | Times Cited: 41
Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity
Ashley Jia Wen Yip, Zheng Yao Low, Vincent Chow, et al.
Viruses (2022) Vol. 14, Iss. 6, pp. 1345-1345
Open Access | Times Cited: 38
Progress on SARS-CoV-2 3CLpro Inhibitors: Inspiration from SARS-CoV 3CLpro Peptidomimetics and Small-Molecule Anti-Inflammatory Compounds
Jiajie Zhu, Haiyan Zhang, Qinghong Lin, et al.
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 1067-1082
Open Access | Times Cited: 37
Virtual screening and molecular dynamics simulation analysis of Forsythoside A as a plant-derived inhibitor of SARS-CoV-2 3CLpro
Shabana Bibi, Muhammad Saad Khan, Sherif A. El-Kafrawy, et al.
Saudi Pharmaceutical Journal (2022) Vol. 30, Iss. 7, pp. 979-1002
Open Access | Times Cited: 35
Viral proteases as therapeutic targets
Taťána Majerová, Jan Konvalinka
Molecular Aspects of Medicine (2022) Vol. 88, pp. 101159-101159
Open Access | Times Cited: 35
Synthesis of Dihydrobenzofuro[3,2‐b]chromenes as Potential 3CLpro Inhibitors of SARS‐CoV‐2: A Molecular Docking and Molecular Dynamics Study
Sudip Gorai, Vivek Junghare, Kshama Kundu, et al.
ChemMedChem (2022) Vol. 17, Iss. 8
Open Access | Times Cited: 34
Page 1 - Next Page

Scroll to top